EGFR tyrosine kinase inhibitors (Temple University)

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameEGFR tyrosine kinase inhibitors (Temple University)
Drug Alias NameEGFR tyrosine kinase inhibitors (Onconova Therapeutics)ON-38600
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTemple University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTraws Pharma IncTemple University
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A